Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; povidone; crospovidone; magnesium stearate; lactose monohydrate; maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; maize starch; povidone; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - leflunomide generichealth is indicated for the treatment of: - active rheumatoid arthritis; - active psoriatic arthritis. leflunomide generichealth is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.,the combined use of leflunomide generichealth with other disease modifying anti-rheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 100 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; colloidal anhydrous silica; crospovidone; maize starch; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

European Union - English - EMA (European Medicines Agency)

zentiva k.s. - leflunomide - arthritis, rheumatoid; arthritis, psoriatic - immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard);active psoriatic arthritis.recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - leflunomide 10mg - film coated tablet - 10 mg - active: leflunomide 10mg excipient: colloidal silicon dioxide low substituted hydroxypropyl cellulose lactose lactose monohydrate magnesium stearate maize starch opadry white 04f58804 povidone

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspire pharma ltd - leflunomide - tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - leflunomide - tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva - leflunomide - tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - leflunomide - tablet - 10mg

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide 20 mg - leflunomide tablets are indicated in adults for the treatment of active rheumatoid arthritis (ra): - to reduce signs and symptoms - to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing - to improve physical function (see clinical studies). aspirin, nonsteroidal anti-inflammatory agents and/or low dose corticosteroids may be continued during treatment with leflunomide tablets (see precautions - drug interactions – nsaids). the combined use of leflunomide tablets with antimalarials, intramuscular or oral gold, d penicillamine, azathioprine, or methotrexate has not been adequately studied. (see warnings - immunosuppression potential/bone marrow suppression). leflunomide tablets are contraindicated in patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. leflunomide tablets can cause fetal harm when administered to a pregnant woman. leflunomide, when administered orally to rats during organogenesis at a dose of 15 mg/kg, was ter